Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SLN Silence Therapeutics Plc
- Stocks
- Healthcare
- NASDAQ: SLN
Price (delayed)
$4.37
Market cap
$206.19M
P/E Ratio
N/A
Dividend/share
N/A
EPS
N/A
Enterprise value
$141.36M
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform
Highlights
Silence Therapeutics's debt has plunged by 83% YoY and by 49% from the previous quarter
The equity has plunged by 173% YoY but it is up by 16% from the previous quarter
Silence Therapeutics's net income has plunged by 63% YoY and by 58% from the previous quarter
The gross profit has contracted by 40% from the previous quarter and by 19% YoY
Key stats
What are the main financial stats of SLN
Market
Valuations
Earnings
Shares outstanding
47.18M
Market cap
$206.19M
Enterprise value
$141.36M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
7.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.07
Revenue
$27.89M
Gross profit
$18.79M
Operating income
-$86.53M
Net income
-$71.49M
EBIT
-$68.59M
EBITDA
-$68M
Free cash flow
-$70.8M
Per share
Balance sheet
Liquidity
EPS
N/A
EPS diluted
N/A
Free cash flow per share
-$1.5
Book value per share
-$2.39
Revenue per share
$0.59
TBVPS
$3.71
Total assets
$185.3M
Total liabilities
$72.56M
Debt
$60,000
Equity
-$112.74M
Working capital
$150.53M
Debt to equity
0
Current ratio
8.81
Quick ratio
7.09
Net debt/EBITDA
0.95
Margins
Efficiency
Dividend
EBITDA margin
-243.8%
Gross margin
67.4%
Net margin
-256.3%
Operating margin
-310.2%
Return on assets
-34.2%
Return on equity
-2,380.9%
Return on invested capital
-86.7%
Return on capital employed
-41.3%
Return on sales
-245.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SLN stock price
How has the Silence Therapeutics stock price performed over time
Intraday
8.98%
1 week
18.11%
1 month
50.69%
1 year
-80.95%
YTD
-36.48%
QTD
54.96%
Financial performance
How have Silence Therapeutics's revenue and profit performed over time
Revenue
$27.89M
Gross profit
$18.79M
Operating income
-$86.53M
Net income
-$71.49M
Gross margin
67.4%
Net margin
-256.3%
Silence Therapeutics's net margin has plunged by 145% from the previous quarter and by 94% YoY
The operating margin has dropped by 112% since the previous quarter and by 88% year-on-year
Silence Therapeutics's net income has plunged by 63% YoY and by 58% from the previous quarter
SLN's operating income has shrunk by 58% YoY and by 37% QoQ
Price vs fundamentals
How does SLN's price correlate with its fundamentals
Growth
What is Silence Therapeutics's growth rate over time
Valuation
What is Silence Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
7.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.07
The equity has plunged by 173% YoY but it is up by 16% from the previous quarter
The P/S is 74% lower than the 5-year quarterly average of 28.2 and 67% lower than the last 4 quarters average of 22.7
SLN's revenue is down by 36% from the previous quarter and by 16% YoY
Efficiency
How efficient is Silence Therapeutics business performance
Silence Therapeutics's return on sales has shrunk by 139% QoQ and by 112% YoY
SLN's ROA has plunged by 68% from the previous quarter and by 17% YoY
SLN's ROIC is down by 46% from the previous quarter but it is up by 13% YoY
Dividends
What is SLN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SLN.
Financial health
How did Silence Therapeutics financials performed over time
The total assets is 155% more than the total liabilities
Silence Therapeutics's quick ratio has decreased by 38% YoY and by 20% QoQ
Silence Therapeutics's current ratio has decreased by 31% YoY and by 21% from the previous quarter
Silence Therapeutics's debt is 100% more than its equity
The equity has plunged by 173% YoY but it is up by 16% from the previous quarter
Silence Therapeutics's debt has plunged by 83% YoY and by 49% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.